Scholarlink

Background <p>The efficacy of adjuvant chemotherapy for gastric cancer (GC) in adult patients aged ≥ 80 years remains unclear because this population is often underrepresented in clinical trials. This study aimed to evaluate the impact of S-1 adjuvant chemotherapy on this age group following curative gastrectomy.</p> Patients and Methods <p>This retrospective multicenter study included 113 patients aged ≥ 80 years with pathological stage II/III GC who underwent curative D2 or D1+ gastrectomy between 2008 and 2020. Patients were classified according to whether they had received S-1 adjuvant chemotherapy. Overall survival (OS), recurrence-free survival (RFS), adverse events, and relative dose intensity (RDI) were analyzed.</p> Results <p>Among the patients, 30 received S-1 and 83 underwent surgery alone. Baseline characteristics were generally balanced, although the S-1 group had a higher rate of D2 dissection and shorter postoperative hospital stays. The 5-year OS and RFS rates were significantly higher in the S-1 group (70.0% and 66.7%, respectively) than in the nonchemotherapy group (48.1% and 45.7%, respectively). Multivariable analysis confirmed S-1 administration as an independent prognostic factor for both OS and RFS. Grade ≥ 3 adverse events occurred in 22.3% of patients who received S-1. Patients who maintained an RDI ≥ 60% demonstrated improved RFS.</p> Conclusions <p>Adjuvant chemotherapy with S-1 may improve survival in patients aged ≥ 80 years with stage II/III GC. Maintaining an adequate dose intensity appears to be critical for clinical benefits in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection: A Multicenter Cohort Study

  • 期刊论文

  • 发表日期：

    2025年9月24日

查看全文
  • Shutaro Sumiyoshi,
  • Takeshi Kubota,
  • Hiroyuki Inoue,
  • Kazuya Takabatake,
  • Keiji Nishibeppu,
  • Junichi Hamada,
  • Toshiya Ochiai,
  • Yosuke Ariyoshi,
  • Atsushi Toma,
  • Kenji Watanabe,
  • Nobuki Yamaoka,
  • Soujin Sai,
  • Shozo Ide,
  • Tomoya Hatakeyama,
  • Yoshiki Itokawa,
  • Fumiaki Ochi,
  • Hirotaka Konishi,
  • Hitoshi Fujiwara,
  • Miho Sekimoto,
  • Satoru Shikata,
  • Atsushi Shiozaki

摘要

Background

The efficacy of adjuvant chemotherapy for gastric cancer (GC) in adult patients aged ≥ 80 years remains unclear because this population is often underrepresented in clinical trials. This study aimed to evaluate the impact of S-1 adjuvant chemotherapy on this age group following curative gastrectomy.

Patients and Methods

This retrospective multicenter study included 113 patients aged ≥ 80 years with pathological stage II/III GC who underwent curative D2 or D1+ gastrectomy between 2008 and 2020. Patients were classified according to whether they had received S-1 adjuvant chemotherapy. Overall survival (OS), recurrence-free survival (RFS), adverse events, and relative dose intensity (RDI) were analyzed.

Results

Among the patients, 30 received S-1 and 83 underwent surgery alone. Baseline characteristics were generally balanced, although the S-1 group had a higher rate of D2 dissection and shorter postoperative hospital stays. The 5-year OS and RFS rates were significantly higher in the S-1 group (70.0% and 66.7%, respectively) than in the nonchemotherapy group (48.1% and 45.7%, respectively). Multivariable analysis confirmed S-1 administration as an independent prognostic factor for both OS and RFS. Grade ≥ 3 adverse events occurred in 22.3% of patients who received S-1. Patients who maintained an RDI ≥ 60% demonstrated improved RFS.

Conclusions

Adjuvant chemotherapy with S-1 may improve survival in patients aged ≥ 80 years with stage II/III GC. Maintaining an adequate dose intensity appears to be critical for clinical benefits in this population.